Cardiac Allograft Vasculopathy
- 16 September 1997
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 96 (6) , 2069-2077
- https://doi.org/10.1161/01.cir.96.6.2069
Abstract
Cardiac allograft vasculopathy (CAV) remains a troublesome long-term complication of heart transplantation. It is manifested by a unique and unusually accelerated form of coronary disease affecting both intramural and epicardial coronary arteries and veins. CAV is characterized by vascular injury induced by a variety of noxious stimuli, including the immune system response to the allograft, ischemia-reperfusion injury, viral infection, immunosuppressive drugs, and classic risk factors such as hyperlipidemia, insulin resistance, and hypertension. The obstructive vascular lesions are thought to progress through repetitive endothelial injury followed by repair response. The role of major histocompatibility complex donor-recipient differences in the pathogenesis of CAV has not yet been completely elucidated. Intracoronary ultrasound studies reveal a dual morphology with donor-transmitted or de novo focal, noncircumferential plaques in proximal segments and/or a diffuse, concentric pattern observed in distal segments. A lack of correlation between microvascular and epicardial vessel disease suggests discordant manifestations and progression of CAV. Apoptosis and loss of functional vascular remodeling have to be considered as important mediators of clinically relevant CAV. Strategies for blocking T-cell costimulation and expression of adhesion molecules may help prevent chronic rejection in clinical transplantation. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and antiproliferative drugs may slow progression of CAV by various effects. Methods to augment endogenous nitric oxide bioavailability as well as newer immunosuppressive regimens may be protective. Balloon angioplasty has a limited role in the treatment of focal lesions. Experiences with coronary stenting, coronary artery bypass grafting, and transmyocardial laser revascularization are limited. Retransplantation has a worse outcome than initial transplantation.Keywords
This publication has 53 references indexed in Scilit:
- Time course of endothelial function in epicardial conduit coronary arteries and in the microcirculation in the long-term follow-up after cardiac transplantationInternational Journal of Cardiology, 1996
- Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis.Journal of Clinical Investigation, 1996
- PHARMACOLOGICALLY INDUCED REGRESSION OF CHRONIC TRANSPLANT REJECTIONTransplantation, 1995
- Immunopathology of cardiac transplant rejectionCurrent Opinion in Cardiology, 1995
- Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa HypercholesterolemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factorsThe American Journal of Cardiology, 1994
- Metabolic risk factors for atherosclerosis in heart transplant recipientsAmerican Heart Journal, 1994
- Reversal of lovastatin‐mediated inhibition of natural killer cell cytotoxicity by interleukin 2Journal of Cellular Physiology, 1990
- Successful coronary artery bypass grafting for high-risk left main coronary artery atherosclerosis after cardiac transplantationThe Annals of Thoracic Surgery, 1990
- Retransplantation for severe accelerated coronary artery disease in heart transplant recipientsThe American Journal of Cardiology, 1988